Company intelligence / Profile preview

YSLAB

Quimper, Brittany, Franceyslab.fr ↗

Ownership: Private
Development stage: Commercial

Overview

YSLAB has over 20 years of experience developing and manufacturing medical devices and healthcare products based on marine actives. Its CE-marked products are commercialized globally in more than 60 countries. The company holds patents such as for "Lacrymer®", a controlled ionized marine solution recognized by the French National Academy of Pharmacy for its work on P2X7 death receptor involvement in eye disorders[1]. Clinical results per se are not detailed publicly.

Therapeutic areas: OtherRheumatologyOphthalmologyInfectious Diseases
Modalities: Live biotherapeutic product therapy (marine actives)Device (nasal/ear/throat sprays)Food supplement
Industry: Consumable Medical Devices

Partnerships

Global distributorsPrivate label partners

Beyond the preview

Go deeper on YSLAB.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on YSLAB.

Explore the full profile